Amgen and AstraZeneca announced a collaborative development of a combination therapy.
2 reports, 1 independent
Updated Sep 8
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Amgen and AstraZeneca announced a collaborative development of a combination therapy.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Joint drug trial success boosts Amgen stock.Sub-event
Amgen and AstraZeneca are collaborating on a new combination therapy.1 source
Keep exploring
The entities involved
-
Amgen
American multinational biopharmaceutical company
-
AstraZeneca
British-Swedish pharmaceutical company
Related events
- Alnylam Pharmaceuticals announced new partnerships with AstraZeneca for drug development and with Ionis Pharmaceuticals for clinical trials.
- Amgen and AstraZeneca partnered on a Phase 3 CROSSING trial for the drug TEZSPIRE.
- Amgen acquired Horizon Therapeutics, a company whose portfolio included a drug discovered by AstraZeneca.